New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions episode artwork

EPISODE · Jun 18, 2026 · 22 MIN

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

from JAMA Medical News

Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content: A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026

NOW PLAYING

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

0:00 22:49

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of JAMA Medical News?

This episode is 22 minutes long.

When was this JAMA Medical News episode published?

This episode was published on June 18, 2026.

What is this episode about?

Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on...

Can I download this JAMA Medical News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!